Epigenomics set to bring products to public with Roche deal
This article was originally published in Clinica
Executive Summary
Epigenomics' star is rising. Alexander Olek, the German company's CEO explains how a decisive new deal promises to launch the four-year-old biotechnology firm into the fast lane. Neena Brizmohun reports